Aligos Therapeutics【ALGS】銘柄情報

Aligos Therapeutics Inc (ALGS) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

5.80

( 6.81% )

買値

5.69

売値

5.81

出来高

68,973

5.3216 日の範囲 5.85

4.80 52 週間の範囲 13.6892

時価総額

35.892M

前日終値

5.43

始値

5.38

時刻

5.7701

最終取引時間

04:05:43

財務取引量

US$ 389,353

VWAP

5.645

平均取引量 (3 か月)

US$ 215,708

発行済株式数

6,188,223

配当利回り

PER

-0.64

1 株当たり利益 (EPS)

-2.77

歳入

4.71M

純利益

-90.32M

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment ... Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.aligos.com

本社

South San Francisco, United States

設立

2026

Aligos Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ALGS. The last closing price for Aligos Therapeutics was US$5.43. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 4.80 to US$ 13.6892.

Aligos Therapeutics currently has 6,188,223 shares in issue. The market capitalisation of Aligos Therapeutics is US$35.89 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.64.

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.19	3.38680926916	5.61	5.94	5.3	49399	5.55511709	CS
4	0.44	8.20895522388	5.36	5.94	4.8	79060	5.28583112	CS
12	-2.34	-28.7469287469	8.14	8.97	4.8	225957	6.81287503	CS
26	-3.77	-39.3939393939	9.57	10.49	4.8	134899	7.03759345	CS
52	-1.49	-20.438957476	7.29	13.6892	4.8	106836	7.90611746	CS
156	4.88	530.434782609	0.92	46.8	0.3482	211927	8.07052749	CS
260	-15.36	-72.5897920605	21.16	46.8	0.3482	237172	6.60675527	CS